Cover Image

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

The DNA repair enzymeO6-methylguanine-DNA methyltransferase (MGMT) antagonizes the effects of alkylating agents, and its expression is associated with resistance to cancer therapy based on these compounds. Weller et al. consider the prognostic and predictive value of MGMT gene silencing in gliomas...

Full description

Saved in:
Bibliographic Details
Main Authors: Weller, Michael (Author) , Stupp, Roger (Author) , Reifenberger, Guido (Author) , Brandes, Alba A. (Author) , Van den Bent, Martin J. (Author) , Wick, Wolfgang (Author) , Hegi, Monika E. (Author)
Format: Article (Journal)
Language:English
Published: [2010]
In: Nature reviews. Neurology
Year: 2010, Volume: 6, Pages: 39-51
ISSN:1759-4766
DOI:10.1038/nrneurol.2009.197
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/nrneurol.2009.197
Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/nrneurol.2009.197
Get full text
Author Notes:Michael Weller, Roger Stupp, Guido Reifenberger, Alba A. Brandes, Martin J. Van den Bent, Wolfgang Wick, Monika E. Hegi
Description
Summary:The DNA repair enzymeO6-methylguanine-DNA methyltransferase (MGMT) antagonizes the effects of alkylating agents, and its expression is associated with resistance to cancer therapy based on these compounds. Weller et al. consider the prognostic and predictive value of MGMT gene silencing in gliomas and describe the assays that are commonly used to evaluate MGMT status, focusing particularly on MGMT promoter methylation, which is the key mechanism of MGMTgene silencing.
Item Description:Published: 08 December 2009
Gesehen am 23.10.2023
Physical Description:Online Resource
ISSN:1759-4766
DOI:10.1038/nrneurol.2009.197

Similar Items